[Floxuridine-containing regime in the treatment of gestational trophoblastic tumor].

Abstract

OBJECTIVE:

To analyse the efficacy of the floxuridine (FUDR)-containing regime (single agent or in combination) in the treatment of gestational trophoblastic tumor.

METHODS:

Seventy-four patients with gestational trophoblastic tumors (GTT), 47 invasive mole and 27 choriocarcinoma, were treated with FUDR-containing regime. The clinical staging of the disease were: 33 cases of stage I, 3 cases of stage II, 31 cases of stage IIIa, 6 cases of stage IIIb, and 1 case of stage IV.

RESULTS:

The cure rate of FUDR-containing regime in the treatment of GTT was 91.9% (68 out of 74 cases). Twenty-one out of these 74 patients showed drug resistant to 5-FU-containing or MTX-containing regime and were cured after they changed to the FUDR-containing regime. All 7 patients of advanced stage (> or = III b) got cured. The major adverse event of FUDR-containing regime was myelodepression and gastrointestinal toxicity: III-IV degree granulopenia 26%, III-IV thrombopenia 6.2%, III degree vomiting 57.1%, and III degree diarrhea 4.3%.

CONCLUSION:

FUDR-containing regime is efficient for the treatment of GTT, even for those with advanced stage or drug-resistant disease.

• Authors: Xi-run Wan, Xiu-yu Yang, Yang Xiang, Yu Wu, Yan-mei Yang, Shu-jie Yin, Jie Li
• Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae (Zhongguo Yi Xue Ke Xue Yuan Xue Bao) Vol. 25 Issue 4 Pg. 410-3 (Aug 2003) ISSN: 1000-503X [Print] China
• PMID: 12974084 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Floxuridine
• Dactinomycin
• Vincristine

Topics

• Adolescent
• Adult
• Antimetabolites, Antineoplastic (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Choriocarcinoma (drug therapy)
• Dactinomycin (administration & dosage)
• Drug Administration Schedule
• Female
• Floxuridine (administration & dosage)
• Gestational Trophoblastic Disease (drug therapy)
• Humans
• Hydatidiform Mole, Invasive (drug therapy)
• Middle Aged
• Pregnancy
• Uterine Neoplasms (drug therapy)
• Vincristine (administration & dosage)